Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal



This summary information comes from assessment reports and Fass.


Persistence. It cannot be excluded that umeclidinium is persistent, due to the lack of data.
Bioaccumulation. Umeclidinium has low potential for bioaccumulation.
Toxicity. Umeclidinium has high chronic toxicity.
Risk. The use of umeclidinium (sales data Sweden 2018) has been considered to result in insignificant environmental risk.

Detailed information

Assessment report

Assessment report for Anoro (umeclidinium, vilanterol) 28 March 2014 EMA/CHMP/163509/2014 and Laventair (umeclidinium, vilanterol) 28 March 2014 EMA/CHMP/163506/2014.


Persistence: No data.

Bioaccumulation: log Kow = 1.256, conclusion not B.

Chronic toxicity: There are data for 3 trophic levels, most sensitive alge NOEC 62.5 microg/L.


The risk, PEC/PNEC, calculated from data in the assessment report from a European perspective:

PECsurfacewater = 0.00063 microg/L. "The PECsurfacewater is below 0.01 μg/L, and thus a phase II assessment is not necessary."

PNEC = Lowest NOEC, 62.5 microg/L/10 (Assessment Factor (AF) for 3 chronic studies) = 6.25 microg/L.

PEC/PNEC = 0,00010 which gives the risk insignificant.

Fass environmental information

Fass environmental information for Anoro Ellipta (umeclidinium, vilanterol) from GlaxoSmithKline (downloaded 2022-01-18).


Persistence: No data.

Bioaccumulation: Log Dow at pH 5 = 0.092, Log Dow at pH 7 = 1.35, Log Dow at pH 9 = 1.39.

Chronic toxicity: here are data for 3 trophic levels, most sensitive green alge NOEC 95.4 microg/L.


PEC/PNEC is based on expected sales in Sweden during 2018. PEC/PNEC = 1.68 x 10-6 which gives the risk insignificant.

Author: Health and Medical Care Administration, Region Stockholm